Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Extract

It has been 50 years since Dr. William B. Kannel coined the term “factors of risk” in relation to cardiovascular disease (1). Since then, clinical risk assessment, including the use of circulating biomarkers, has become an integral part of medical practice. The current era of genomics, proteomics, and metabolomics is projected to lead to the discovery of an immense number of novel candidate biomarkers. With that in mind, the American Heart Association recently issued a statement emphasizing the critical appraisal of novel risk markers to determine their clinical utility (2). Although very few candidate biomarkers will likely survive the test of time (3), the study by Rohatgi et al. published in the present issue of Clinical Chemistry demonstrates the strengths of one such biomarker, growth differentiation factor 15 (GDF-15),2 as a prognostic marker in the community (4).

In this report from the Dallas Heart Study, the authors describe their investigation of the association of GDF-15 with subclinical coronary atherosclerosis and mortality. Increasing circulating GDF-15 concentrations were cross-sectionally associated with cardiovascular risk factors and coronary artery calcium. More importantly, GDF-15 was a significant predictor of all-cause and cardiovascular mortality independent of traditional risk factors and other novel biomarkers (high-sensitivity C-reactive protein, N-terminal pro–B-type natriuretic peptide, and high-sensitivity cardiac troponin T).

Issue Section:
Editorials
You do not currently have access to this article.
Download all slides